1-7 of 7
Chad A Hudson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AML

Jacqueline A. Cook, Loren Lott, Jenna Perry, Ashley M. Eckel, Dongbin Xu, Chad A. Hudson, Denise A. Wells, Michael R. Loken, Andrew J. Menssen
Journal: Blood
Blood (2024) 144 (5): 581–585.
https://doi.org/10.1182/blood.2024024264
Published: 2024
Includes: Supplemental data
Journal Articles

Residual Mast Cells Can Explain Persistent Molecular Positivity in Difference from Normal Flow Cytometric-Defined MRD Negative Core Binding Factor AML

Jacqueline A. Cook, Loren Lott, Jenna Perry, Arun Nalla, Dongbin Xu, Chad A. Hudson, Denise A. Wells, Michael R. Loken, Andrew J. Menssen
Journal: Blood
Blood (2023) 142 (Supplement 1): 426.
https://doi.org/10.1182/blood-2023-180275
Published: 2023
Journal Articles

CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children's Oncology Group AAML1031 Protocol

Andrew J. Menssen, Chad A. Hudson, Todd A. Alonzo, Robert B. Gerbing, Laura Pardo, Fan-Chi Hsu, Loren L. Lott, Fangyan Dai, Keely Ghiradelli, Yi-Cheng Wang, E. Anders Kolb, Todd M. Cooper, Jessica A. Pollard, Michael R. Loken, Richard Aplenc, Lisa Eidenschink Brodersen, Soheil Meshinchi
Journal: Blood
Blood (2022) 140 (Supplement 1): 3452–3453.
https://doi.org/10.1182/blood-2022-163682
Published: 2022
Journal Articles

A Novel Multi-Analytic Clinical Diagnostic Assay to Detect HLA Loss of Heterozygosity in Post-Hematopoietic Cell Transplant Relapse Patients

David Dinauer, Jennifer Schiller, James Nytes, Dina Berchanskiy, Rita Glumm, Susan Gaba, Michael Janasik, Chad A. Hudson, Lisa Eidenschink Brodersen, Wayne Fritschle, Matthew W. Anderson
Journal: Blood
Blood (2022) 140 (Supplement 1): 4964–4965.
https://doi.org/10.1182/blood-2022-159509
Published: 2022
Journal Articles

Pediatric Acute Myeloid Leukemia with Co-Occurring BCR::ABL and CBFA2T3::GLIS2 Dual Fusion with Deep Response to FOLR1-Targeting Antibody Drug Conjugate Stro-002 and Tyrosine Kinase Inhibitor

Kasey Andrews, Soheil Meshinchi, Preethi Marri, Abdul H. Siddiqui, Jacek Polski, Arturo Molina, Joseph Chewning, Lisa Eidenschink Brodersen, Chad A. Hudson, Hamayun Imran
Journal: Blood
Blood (2022) 140 (Supplement 1): 11757–11758.
https://doi.org/10.1182/blood-2022-164629
Published: 2022
Journal Articles

Increased Expression of CD56 on Plasmacytoid Dendritic Cells in Myeloid Leukemia Associated with Down Syndrome (ML-DS) Is Normal Regeneration and Not Measurable Residual Disease

Chad A Hudson, Laura Pardo, Loren L. Lott, Michael R. Loken, Lisa Eidenschink Brodersen
Journal: Blood
Blood (2021) 138 (Supplement 1): 3433.
https://doi.org/10.1182/blood-2021-149873
Published: 2021
Journal Articles

Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol

Lisa Eidenschink Brodersen, PhD, Chad A. Hudson, MDPhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Laura Pardo, Amanda R. Leonti, MS, Timothy P. Singleton, MD, Fan-Chi Hsu, PhD, Loren L. Lott, Fangyan Dai, Keely Ghiradelli, E. Anders Kolb, MD, Todd M. Cooper, DO, Jessica A. Pollard, MD, Michael R. Loken, PhD, Richard Aplenc, MD PhD, Soheil Meshinchi, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39.
https://doi.org/10.1182/blood-2020-142659
Published: 2020